JOP20230269A1 - العلاج بالخلايا التائية لمستقبلات المستضد الخيميري المحددة cd19 - Google Patents

العلاج بالخلايا التائية لمستقبلات المستضد الخيميري المحددة cd19

Info

Publication number
JOP20230269A1
JOP20230269A1 JOJO/P/2023/0269A JOP20230269A JOP20230269A1 JO P20230269 A1 JOP20230269 A1 JO P20230269A1 JO P20230269 A JOP20230269 A JO P20230269A JO P20230269 A1 JOP20230269 A1 JO P20230269A1
Authority
JO
Jordan
Prior art keywords
cell therapy
chimeric antigen
antigen receptors
specific chimeric
specific
Prior art date
Application number
JOJO/P/2023/0269A
Other languages
Arabic (ar)
English (en)
Inventor
Reyner Jordi Esteve
Ispizua Álvaro Urbano
Capdevila Mariona Pascal
Barado Ana Boronat
Otero Manel Juan
González Julio Delgado
Castellà María Castellà
Ribes Jordi Yagüe
Original Assignee
Fundacio De Recerca Clinic Barcelona Inst Dinvestigacions Biomediques August Pi I Sunyer
Hospital Clinic Barcelona
Univ Barcelona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio De Recerca Clinic Barcelona Inst Dinvestigacions Biomediques August Pi I Sunyer, Hospital Clinic Barcelona, Univ Barcelona filed Critical Fundacio De Recerca Clinic Barcelona Inst Dinvestigacions Biomediques August Pi I Sunyer
Publication of JOP20230269A1 publication Critical patent/JOP20230269A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JOJO/P/2023/0269A 2021-05-06 2023-10-26 العلاج بالخلايا التائية لمستقبلات المستضد الخيميري المحددة cd19 JOP20230269A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/ES2021/070316 WO2022234158A1 (es) 2021-05-06 2021-05-06 Terapia de células t con receptor de antígeno quimérico específico de cd19
PCT/EP2022/062374 WO2022234134A1 (en) 2021-05-06 2022-05-06 Cd19-specific chimeric antigen receptor t-cell therapy

Publications (1)

Publication Number Publication Date
JOP20230269A1 true JOP20230269A1 (ar) 2023-10-26

Family

ID=76355528

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2023/0269A JOP20230269A1 (ar) 2021-05-06 2023-10-26 العلاج بالخلايا التائية لمستقبلات المستضد الخيميري المحددة cd19

Country Status (11)

Country Link
US (1) US20240398945A1 (https=)
EP (1) EP4334357A1 (https=)
JP (1) JP2024519529A (https=)
AU (1) AU2022270952A1 (https=)
BR (1) BR112023023061A2 (https=)
CA (1) CA3219214A1 (https=)
CL (1) CL2023003299A1 (https=)
CO (1) CO2023016940A2 (https=)
JO (1) JOP20230269A1 (https=)
MX (1) MX2023013088A (https=)
WO (2) WO2022234158A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025040765A (ja) * 2023-09-12 2025-03-25 国立大学法人三重大学 Ｃａｒをコードする核酸分子とそれを含むベクター、ｃａｒ、ｃａｒを含む免疫細胞とその細胞を含む医薬組成物、細胞傷害活性を向上させる方法、並びにｃａｒを含む免疫細胞の製造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY35468A (es) * 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
FI2997141T3 (fi) * 2013-05-13 2022-12-15 CD19-spesifinen kimeerinen antigeenireseptori ja sen käyttöjä
KR102136063B1 (ko) * 2017-12-06 2020-07-22 앱클론(주) 악성 b 세포를 특이적으로 인지하는 항체 또는 그의 항원 결합 단편, 이를 포함하는 키메라 항체 수용체 및 이의 용도
WO2019119822A1 (en) * 2017-12-23 2019-06-27 Uwell Biopharma Inc. Pharmaceutical chimeric receptor composition and method thereof
CN108047332B (zh) * 2018-01-15 2021-08-24 阿思科力(苏州)生物科技有限公司 以cd19为靶点的特异性抗体、car-nk细胞及其制备和应用
US12331114B2 (en) * 2018-02-13 2025-06-17 Indian Institute Of Technology Bombay Humanized anti-CD19 chimeric antigen receptor, its nucleic acid sequence and its preparation
WO2020180551A1 (en) * 2019-03-05 2020-09-10 Promab Biotechnologies, Inc. Car-t cells with humanized cd19 scfv
EP3773918A4 (en) * 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY

Also Published As

Publication number Publication date
CL2023003299A1 (es) 2024-07-05
CO2023016940A2 (es) 2024-02-05
JP2024519529A (ja) 2024-05-15
US20240398945A1 (en) 2024-12-05
BR112023023061A2 (pt) 2024-01-30
AU2022270952A1 (en) 2023-11-16
EP4334357A1 (en) 2024-03-13
MX2023013088A (es) 2024-01-24
WO2022234158A1 (es) 2022-11-10
CA3219214A1 (en) 2022-11-10
WO2022234134A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
CL2020003026A1 (es) Anticuerpos anti-sirpa y métodos de utilización de los mismos
CO2020000438A2 (es) Anticuerpos anti-ctla-4 y sus usos
CR20220545A (es) ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRA EL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2)
CR20200467A (es) Agentes anticuerpos anti-cd25
EA201991005A1 (ru) Антитела и полипептиды, направленные против cd127
JOP20200292A1 (ar) Bcma / cd3 و gprdc5d / cd3 مضادات غير محددة للاستخدام في علاج السرطان
EA201892294A1 (ru) Антитела и композиции против tim-3
EA202092306A1 (ru) Анти-cd24 композиции и их применения
CL2017003261A1 (es) Factor xi anticuerpos y métodos de uso
EA202191785A1 (ru) Антитела к ctla4 и способы их применения
MX373382B (es) Diacuerpos monovalentes bi-especificos que son capaces de enlazar a gpa33 y cd3, y sus usos.
BR112016003417A2 (pt) diacorpo otimizado por sequência capaz de se ligar especificamente a um epitopo de cd123 e a um epitopo de cd3, diacorpo biespecífico capaz de se ligar especificamente a um epitopo de cd123 e a um epitopo de cd3, composição farmacêutica, e uso da composição farmacêutica
PH12017502013A1 (en) Anti-ox40 antibodies and methods of use thereof
PH12020552235A1 (en) Anti-cd40 antibodies for use in treating autoimmune disease
SA523440622B1 (ar) أجسام مضادة
CR11243A (es) Anticuerpos humanos contra cd20 humano y metodo para utilizarlos
MX2009002414A (es) Anticuerpos anti-cd19 humanizados y su uso en el tratamiento de oncologia, transplante y enfermedad autoinmunitaria.
PH12021552415A1 (en) Rituximab-resistant chimeric antigen receptors and uses thereof
EA202090791A1 (ru) Агонистические антитела против cd40
MX2024011278A (es) Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer.
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
MX2021003673A (es) Anticuerpos anti-vsig4 humano y usos de los mismos.
EA201992278A1 (ru) Способы и композиции для снижения иммуногенности
MX2020009902A (es) Anticuerpos con especificidad dual para pd-l1 y pd-l2 humanos y metodos de uso de los mismos.
JOP20230269A1 (ar) العلاج بالخلايا التائية لمستقبلات المستضد الخيميري المحددة cd19